CLSD Clearside Biomedical Inc.

1.4
-0.07  -5%
Previous Close 1.47
Open 1.48
Price To Book 2.12
Market Cap 50454943
Shares 36,039,245
Volume 541,534
Short Ratio
Av. Daily Volume 1,141,345

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released May 31, 2018 - mixed data. 12.3 ETDRS letters compared to 13.5 ETDRS letters in control arm.
Suprachoroidal CLS-TA - TYBEE
Diabetic Macular Edema (DME)
Phase 1/2 trial completed 4Q 2017.
Suprachoroidal CLS-TA - HULK
Diabetic macular edema (DME)
Phase 3 data released November 5, 2018 did not meet primary endpoint.
Suprachoroidal CLS-TA - SAPPHIRE
Macular edema associated with retinal vein occlusion (RVO)
PDUFA date October 19, 2019.
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis
Phase 3 commencement of enrollment announced March 6, 2018.
Suprachoroidal CLS-TA - TOPAZ
Macular edema associated with retinal vein occlusion (RVO)

Latest News

  1. Edited Transcript of CLSD earnings conference call or presentation 12-Mar-19 9:00pm GMT
  2. Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  3. Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference
  4. Clearside Biomedical to Report 2018 Financial Results and Provide Corporate Update on Tuesday, March 12, 2019
  5. Do Insiders Own Shares In Clearside Biomedical, Inc. (NASDAQ:CLSD)?
  6. Four Tech Stocks Bubbling with Excitement
  7. Recent Analysis Shows Cisco, Zendesk, Clearside Biomedical, Conn's, NIC, and Commercial Vehicle Group Market Influences — Renewed Outlook, Key Drivers of Growth
  8. Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019
  9. Clearside Biomedical’s Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society
  10. Healthcare Companies Positioned in Major Markets
  11. Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
  12. Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference
  13. Need To Know: Clearside Biomedical, Inc. (NASDAQ:CLSD) Insiders Have Been Buying Shares
  14. Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis
  15. Edited Transcript of CLSD earnings conference call or presentation 8-Nov-18 1:30pm GMT
  16. Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and Upcoming Developments
  17. Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  18. Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference
  19. Today’s Research Reports on Stocks to Watch: Teladoc Health and Clearside
  20. Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow